Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ophthotech Corp    OPHT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

OPHTHOTECH 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Ophthotech Corporation – (OPHT)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/11/2017 | 04:51am CEST

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until March 13, 2017 to file lead plaintiff applications in a securities class action lawsuit against Ophthotech Corporation (NasdaqGS: OPHT). Investor losses must relate to purchases of the Company’s shares between May 11, 2015 and December 12, 2016. This action is pending in the United States District Court for the Southern District of New York.

What You May Do

If you purchased shares of Ophthotech and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com). If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by March 13, 2017.

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on OPHTHOTECH CORP
03/11 OPHTHOTECH 72 HOUR DEADLINE ALERT : Approximately 72 Hours Remain; Former Louisi..
03/09 Lundin Law PC Announces Securities Class Action Lawsuit against Ophthotech Co..
03/09 OPHTHOTECH CORP : Lundin Law PC Announces Securities Class Action Lawsuit agains..
03/08 Lundin Law PC Announces Securities Class Action Lawsuit against Ophthotech Co..
03/08 OPHTHOTECH CORP : Lundin Law PC Announces Securities Class Action Lawsuit agains..
03/07 Lundin Law PC Announces Securities Class Action Lawsuit against Ophthotech Co..
03/07 OPHTHOTECH CORP : Lundin Law PC Announces Securities Class Action Lawsuit agains..
03/06 OPHTHOTECH CORP : Lundin Law PC Announces Securities Class Action Lawsuit agains..
03/03 OPHTHOTECH CORP : Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses ..
03/03 OPHTHOTECH CORP : Khang & Khang LLP Announces Securities Class Action Lawsuit ag..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/24 After Hours Gainers / Losers
03/23 Buy Ophthotech, Get Cash And Zimura For Free
03/10 After Hours Gainers / Losers
02/28 Ophthotech's (OPHT) CEO David Guyer on Q4 2016 Results - Earnings Call Transc..
02/28 Midday Gainers / Losers
Advertisement
Financials ($)
Sales 2017 2,46 M
EBIT 2017 -142 M
Net income 2017 -132 M
Finance 2017 54,5 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 31,0x
EV / Sales 2018 8,06x
Capitalization 131 M
More Financials
Chart OPHTHOTECH CORP
Duration : Period :
Ophthotech Corp Technical Analysis Chart | OPHT | US6837451037 | 4-Traders
Full-screen chart
Technical analysis trends OPHTHOTECH CORP
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 4,29 $
Spread / Average Target 17%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David R. Guyer Chairman & Chief Executive Officer
Glenn P. Sblendorio President, Chief Financial Officer & Treasurer
Keith Westby Chief Operating Officer & Senior Vice President
Harvey N. Masonson Senior Vice President-Clinical Development
Axel Bolte Independent Class II Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
OPHTHOTECH CORP-24.43%131
AMGEN, INC.12.79%121 448
CELGENE CORPORATION7.87%97 137
GILEAD SCIENCES, INC.-5.74%88 227
REGENERON PHARMACEUTIC..4.52%40 701
ACTELION LTD24.40%29 848
More Results